EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial ( COMFORT ‐1)

K A Papp iD, S Beyska-Rizova, M L Gantcheva, E Slavcheva Simeonova, P Brezoev, M Celic, L Groppa, T Blicharski, A Selmanagic, M Kalicka-Dudzik, C A Calin, N Trailovic und 7 weitere

Journal of the European Academy of Dermatology and Venereology · 2024-06 · 38 (6) · 1112-1120

DOI: 10.1111/jdv.19811 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 26.01.2024. Verfasst von K A Papp und 18 weiteren Autor:innen. Beteiligte Einrichtung: Probity Medical Research, Waterloo, Ontario, Canada. Hauptthemen laut MEDLINE: Psoriasis, Thalidomide. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Can-Fite BioPharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

A3 adenosine receptor (A3AR) is overexpressed in the skin and peripheral blood mononuclear cells of psoriasis patients. We investigated the efficacy/safety of piclidenoson (CF101), an orally bioavailable A3AR agonist that inhibits IL‐17 and IL‐23 production in keratinocytes, in moderate‐to‐severe plaque psoriasis.

Methods

The randomized, placebo‐ and active‐controlled, double‐blind phase 3 COMFORT‐1 trial randomized patients (3:3:3:2) to piclidenoson 2 mg BID, piclidenoson 3 mg BID, apremilast 30 mg BID or placebo. At Week 16, patients in the placebo arm were re‐randomized (1:1:1) to piclidenoson 2 mg BID, piclidenoson 3 mg BID or apremilast 30 mg BID. The primary end point was the proportion of patients achieving ≥75% improvement in Psoriasis Area and Severity Index (PASI) from baseline (PASI‐75) at Week 16 versus placebo.

Results

A total of 529 patients were randomized and received ≥1 dose of study medication (safety population). The efficacy analysis population for the primary end point included 426 patients (piclidenoson 2 mg BID, 127; piclidenoson 3 mg BID, 103; apremilast, 118; placebo, 78). Piclidenoson at 2 and 3 mg BID exhibited similar efficacy. The primary end point was met with the 3 mg BID dose: PASI 75 rate of 9.7% versus 2.6% for piclidenoson versus placebo, p = 0.037. The PASI responses with piclidenoson continued to increase throughout the study period in a linear manner. At week 32, analysis in the per‐protocol population showed that a greater proportion of patients in the piclidenoson 3 mg BID arm (51/88, 58.0%) achieved improvement from baseline in Psoriasis Disability Index (PDI) compared to apremilast (59/108, 55.1%), and the test for noninferiority trended towards significance ( p = 0.072). The safety/tolerability profile of piclidenoson was excellent and superior to apremilast.

Conclusions

Piclidenoson demonstrated efficacy responses that increased over time alongside a favourable safety profile. These findings support its continued clinical development as a psoriasis treatment ( ClinicalTrials.gov identifier: NCT03168256).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisThalidomideHumansMaleDouble-Blind MethodFemaleMiddle AgedAdultSeverity of Illness IndexAdenosine

Substanzen

ThalidomideCF101apremilastAdenosine

Autor:innen und Institutionen

  • Probity Medical Research, Waterloo, Ontario, Canada.
  • University of Toronto, Toronto, Ontario, Canada.
  • Multiprofile Hospital for Active Treatment, Pazardzhik, Bulgaria.
  • Diagnostic-Consultative Centre, Sofia, Bulgaria.
  • MHAT Rahila Angelova AD, Pernik, Bulgaria.
  • Diagnostic-Consultative Aleksandrovska, Sofia, Bulgaria.

ORCID-Profile: K A Papp, P Fishman

Förderung

  • Can-Fite BioPharma

Zitieren

APA

Papp, K. A., Beyska-Rizova, S., Gantcheva, M. L., Slavcheva Simeonova, E., Brezoev, P., Celic, M., Groppa, L., Blicharski, T., Selmanagic, A., Kalicka-Dudzik, M., Calin, C. A., Trailovic, N., Ramon, M., Bareket-Samish, A., Harpaz, Z., Farbstein, M., Silverman, M. H., Fishman, P., & COMFORT‐1 Study Investigators (2024). Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial ( COMFORT ‐1). Journal of the European Academy of Dermatology and Venereology, 38(6), 1112-1120. https://doi.org/10.1111/jdv.19811

Vancouver

Papp KA, Beyska-Rizova S, Gantcheva ML, Slavcheva Simeonova E, Brezoev P, Celic M, et al. Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial ( COMFORT ‐1). Journal of the European Academy of Dermatology and Venereology. 2024;38(6):1112-1120. doi:10.1111/jdv.19811

BibTeX
@article{Papp2024,
  author = {Papp, K A and Beyska-Rizova, S and Gantcheva, M L and Slavcheva Simeonova, E and Brezoev, P and Celic, M and Groppa, L and Blicharski, T and Selmanagic, A and Kalicka-Dudzik, M and Calin, C A and Trailovic, N and Ramon, M and Bareket-Samish, A and Harpaz, Z and Farbstein, M and Silverman, M H and Fishman, P and COMFORT‐1 Study Investigators, COMFORT‐1 Study Investigators},
  title = {Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial ( COMFORT ‐1)},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  volume = {38},
  number = {6},
  pages = {1112--1120},
  doi = {10.1111/jdv.19811}
}
Kostenlos starten →